MorphoSys USA, Inc.

11 articles about MorphoSys USA, Inc.

• MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

  4/16/2023

  MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced final five-year follow-up data from the Phase 2 L-MIND study showing that Monjuvi® plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma.

• MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

  9/28/2022

  MorphoSys U.S. Inc. today announced data from the ongoing L-MIND study showing that Monjuvi® (tafasitamab-cxix) plus lenalidomide followed by Monjuvi monotherapy provided long-term efficacy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated for at least 2 years, including six patients on treatment for 5 years or more.

• 

  Pfizer, MorphoSys and Incyte Take Aim at DLBCL in New Collab

  6/14/2022

  MorphoSys U.S. Inc., Pfizer and Incyte are teaming up to test Pfizer’s TTI-622 in conjunction with Monjuvi plus lenalidomide in patients with lymphoma.

• Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47

  6/13/2022

  Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi ® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47.

• National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

  3/15/2022

  MorphoSys U.S. Inc. announced that the National Comprehensive Cancer Network Clinical Practice Guidelines ) in Oncology for B-cell Lymphomas have been updated, and the designation for Monjuvi in combination with lenalidomide is now a Preferred Regimen for second-line therapy in patients with Diffuse Large B-cell Lymphoma who are not candidates for transplant.

• MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  12/11/2021

  MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma.

• Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

  6/4/2021

  Incyte (NASDAQ:INCY) and MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ:MOR), today announced new three-year follow-up data from the ongoing Phase 2 L-MIND study of tafasitamab (Monjuvi®) in combination with lenalidomide in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

• MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

  6/4/2021

  Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

• 

  MorphoSys Pharma's Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma

  6/2/2021

  MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here's everything you need to know about this billion dollars deal.

• Anke Linnartz Joins MorphoSys USA, Inc. As Head Of Corporate Communications And Investor Relations

  11/8/2016

• A Look Back At June In Biotech

  7/12/2004